Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) EBITDA (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of EBITDA data on record, last reported at -$14.2 million in Q3 2025.

  • For Q3 2025, EBITDA rose 6.96% year-over-year to -$14.2 million; the TTM value through Sep 2025 reached -$50.7 million, up 33.87%, while the annual FY2024 figure was -$67.2 million, 60.85% up from the prior year.
  • EBITDA reached -$14.2 million in Q3 2025 per BTAI's latest filing, up from -$15.9 million in the prior quarter.
  • Across five years, EBITDA topped out at -$10.1 million in Q1 2025 and bottomed at -$52.9 million in Q4 2022.
  • Average EBITDA over 4 years is -$29.3 million, with a median of -$24.2 million recorded in 2024.
  • Peak YoY movement for EBITDA: tumbled 62.64% in 2023, then surged 68.34% in 2024.
  • A 4-year view of EBITDA shows it stood at -$52.9 million in 2022, then soared by 62.43% to -$19.9 million in 2023, then skyrocketed by 47.2% to -$10.5 million in 2024, then tumbled by 35.6% to -$14.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$14.2 million in Q3 2025, -$15.9 million in Q2 2025, and -$10.1 million in Q1 2025.